Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

NCT ID: NCT02481219

Last Updated: 2017-03-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 122 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-31
• Study Completion Date: 2016-02-29

Brief Summary

This study is designed to determine the optimal bowel preparation regimen for PillCam® COLON 2 Capsule Endoscopy System (CCE) procedures in average risk patients.

Patients will be randomized to receive one of two bowel preparation regimens prior to PillCam CCE.

Detailed Description

This is a multicenter, prospective, consecutive, randomized study. Average-risk subjects undergoing CCE without optical colonoscopy will be consecutively enrolled and randomized 1:1 to receive one of two bowel preparation regimens prior to PillCam CCE.

Subjects will be enrolled at 5-10 clinical sites in the United States. Subjects who meet the eligibility criteria will be screened for study participation at a baseline visit and will be evaluated on the procedure day or until capsule excretion. A telephone follow-up will be conducted 5 to 9 days post-capsule ingestion to verify capsule excretion, assess patient well-being, and capture any adverse events.

Conditions

Colorectal Cancer Screening

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Bowel preparation regimen -Control

Regimen includes administration of:

Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.

Group Type: ACTIVE_COMPARATOR

PillCam® COLON 2 procedure-CONTROL

Intervention Type: DEVICE

Senna tablets

Intervention Type: DRUG

PEG

Intervention Type: DRUG

Metoclopramide

Intervention Type: DRUG

Erythromycin

Intervention Type: DRUG

SUPREP oral sulfate solution

Intervention Type: DRUG

Bisacodyl

Intervention Type: DRUG

Bowel preparation regimen-Test

Regimen includes administration of:

Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.

Group Type: EXPERIMENTAL

PillCam® COLON 2 procedure-CONTROL

Intervention Type: DEVICE

Senna tablets

Intervention Type: DRUG

PEG

Intervention Type: DRUG

Metoclopramide

Intervention Type: DRUG

Erythromycin

Intervention Type: DRUG

Bisacodyl

Intervention Type: DRUG

SUPREP oral sulfate solution with Gastrografin

Intervention Type: DRUG

Interventions

PillCam® COLON 2 procedure-CONTROL

Intervention Type: DEVICE

Senna tablets

Intervention Type: DRUG

PEG

Intervention Type: DRUG

Metoclopramide

Intervention Type: DRUG

Erythromycin

Intervention Type: DRUG

SUPREP oral sulfate solution

Intervention Type: DRUG

Bisacodyl

Intervention Type: DRUG

SUPREP oral sulfate solution with Gastrografin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subject is between 50 and 75 years of age.

2. Subject is classified as average risk per the American Gastroenterological Association Guidelines on Colorectal Cancer Screening: Individuals without a personal or family history of colorectal cancer (CRC) or adenomas, inflammatory bowel disease, or high-risk genetic syndromes.

3. Subject is willing and able to participate in the study procedures and to understand and sign the informed consent.

Exclusion Criteria

1. Subject with history of polyps (including those identified by computed tomography [CT], optical colonoscopy, sigmoidoscopy, etc.).

2. Subject with history of negative colon assessment (including CT, optical colonoscopy, sigmoidoscopy etc.) within 5 years as these subjects would be defined not requiring screening in this time frame.

3. Subject with suspected or diagnosed with hematochezia, melena, iron deficiency with or without anemia, or any other rectal bleeding, including positive fecal occult blood test of any variety.

4. Subject with any condition believed to have an increased risk of capsule retention such as suspected or known bowel obstruction, stricture, or fistula.

5. Subject with dysphagia or any swallowing disorder.

6. Subject with serious medical conditions that would increase the risk associated with capsule or colonoscopy that are so severe that screening would have no benefit.

7. Subject with a cardiac pacemaker or other implanted electromedical device.

8. Subject expected to undergo MRI examination within 7 days after ingestion of the capsule.

9. Subject with clinical evidence of renal disease, including clinically significant laboratory abnormalities of renal function within the past 6 months, or at any time in the past if not tested within the last 6 months, defined as creatinine, blood urea nitrogen (BUN), and/or glomerular filtration rate (GFR) outside of the local laboratory reference range.

10. Subject with known gastrointestinal motility disorders.

11. Subject with allergies or known contraindication to the medications or preparation agents used in the procedure as described in the relevant instructions for use.

12. Subject with comorbidities which, in the opinion of the investigator, will not be appropriate for the study or the subject has an estimated life expectancy of less than 6 months.

13. Subject is considered to be part of a vulnerable population (e.g. prisoners or those without sufficient mental capacity).

14. Subject is pregnant, suspected pregnant, or is actively breast-feeding. Females of child-bearing potential will be required to provide either a urine pregnancy test or serum pregnancy test as part of the participant's standard of care regardless of their participation in the study (except for subjects who are surgically sterile or are post-menopausal for at least two years).

15. Subject has participated in an investigational drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in this study.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Medtronic - MITG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Douglas K Rex, Dr.

Role: PRINCIPAL_INVESTIGATOR

Locations

Pinnacle Research Group, LLC

Anniston, Alabama, United States

Indiana University Hospital

Indianapolis, Indiana, United States

Indianapolis Gastroenterology and Hepatology

Indianapolis, Indiana, United States

Dayton Gastroenterology

Dayton, Ohio, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Franklin Gastroenterology, PLLC

Franklin, Tennessee, United States

Countries

United States

Other Identifiers

MA-205

Identifier Type: -

Identifier Source: org_study_id